Insider Selling: GenMark Diagnostics, Inc (GNMK) Insider Sells 1,571 Shares of Stock

Insider Selling: GenMark Diagnostics, Inc (GNMK) Insider Sells 1,571 Shares of Stock

GenMark Diagnostics, Inc (NASDAQ:GNMK) insider Hany Massarany sold 1,571 shares of the firm’s stock in a transaction dated Tuesday, May 2nd. The stock was sold at an average price of $13.34, for a total transaction of $20,957.14. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Hany Massarany also recently made the following trade(s):

GenMark Diagnostics, Inc (NASDAQ:GNMK) traded up 0.56% during midday trading on Thursday, hitting $12.65. The stock had a trading volume of 232,805 shares. The stock’s 50 day moving average price is $12.85 and its 200-day moving average price is $12.07. GenMark Diagnostics, Inc has a 52 week low of $5.13 and a 52 week high of $13.62. The company’s market cap is $595.20 million. GenMark Diagnostics (NASDAQ:GNMK) last released its quarterly earnings results on Tuesday, May 2nd. The medical equipment provider reported ($0.30) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.28) by $0.02. The firm earned $12.54 million during the quarter, compared to analyst estimates of $12.55 million. GenMark Diagnostics had a negative net margin of 98.17% and a negative return on equity of 114.35%. Equities research analysts predict that GenMark Diagnostics, Inc will post ($0.96) earnings per share for the current year.

A number of institutional investors have recently added to or reduced their stakes in the stock. FMR LLC raised its position in GenMark Diagnostics by 7.9% in the fourth quarter. FMR LLC now owns 6,960,646 shares of the medical equipment provider’s stock worth $85,198,000 after buying an additional 511,563 shares during the period. Morgan Stanley raised its position in shares of GenMark Diagnostics by 45.5% in the third quarter. Morgan Stanley now owns 2,829,658 shares of the medical equipment provider’s stock worth $33,390,000 after buying an additional 884,575 shares during the last quarter. HighTower Advisors LLC raised its position in shares of GenMark Diagnostics by 4,380.1% in the third quarter. HighTower Advisors LLC now owns 2,074,347 shares of the medical equipment provider’s stock worth $24,477,000 after buying an additional 2,028,046 shares during the last quarter. Northpointe Capital LLC raised its position in shares of GenMark Diagnostics by 25.4% in the first quarter. Northpointe Capital LLC now owns 1,077,196 shares of the medical equipment provider’s stock worth $13,810,000 after buying an additional 217,847 shares during the last quarter. Finally, State Street Corp raised its position in shares of GenMark Diagnostics by 15.0% in the fourth quarter. State Street Corp now owns 734,754 shares of the medical equipment provider’s stock worth $8,994,000 after buying an additional 95,690 shares during the last quarter.

A number of equities analysts have issued reports on GNMK shares. Needham & Company LLC reissued a “buy” rating and issued a $15.00 target price on shares of GenMark Diagnostics in a report on Sunday, April 23rd. Zacks Investment Research cut shares of GenMark Diagnostics from a “hold” rating to a “sell” rating in a report on Thursday, January 26th. Canaccord Genuity reissued a “buy” rating and issued a $14.00 target price on shares of GenMark Diagnostics in a report on Tuesday, February 28th. Finally, BTIG Research reissued a “buy” rating and issued a $17.00 target price on shares of GenMark Diagnostics in a report on Friday, March 10th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. GenMark Diagnostics has an average rating of “Buy” and an average price target of $15.17. GenMark Diagnostics Company Profile

GenMark Diagnostics, Inc is a molecular diagnostics company. The Company is focused on developing and commercializing multiplex molecular tests that aid in the diagnosis of complex medical conditions. It develops and commercializes multiplex molecular tests based on its eSensor electrochemical detection technology.

Related posts

Leave a Comment